Selecta Biosciences initiates Phase 1 clinical study of SEL-212 in gout
10 June 2015 | By Victoria White
Selecta Biosciences has initiated a Phase 1 study to assess the safety, pharmacodynamic profile, and immunogenicity of pegsiticase, a component of SEL-212...